Literature DB >> 17420375

Economic impact of visual impairment and blindness in the United States.

Kevin D Frick1, Emily W Gower, John H Kempen, Jennifer L Wolff.   

Abstract

OBJECTIVES: To assess the economic impact of excess medical and informal care and the health utility loss associated with visual impairment and blindness in adults aged 40 years and older in the United States.
METHODS: Medical Expenditure Panel Survey data from 1996 to 2002 were pooled to estimate the relationship of visual impairment and blindness with total medical expenditures, components of expenditures, days of informal care received, and health utility. Estimates accounting for the complex sampling design were based on regressions including confounders such as comorbidities and demographics. The aggregate economic impact was estimated by projecting average individual effects to the population of individuals with blindness and visual impairment.
RESULTS: Blindness and visual impairment were significantly associated with higher medical care expenditures, a greater number of informal care days, and a decrease in health utility. The home care component of expenditures was most affected by blindness. The aggregate annual economic impact included $5.5 billion spent for medical care and the value of informal care as well as a loss of more than 209,000 quality-adjusted life years.
CONCLUSIONS: Visual impairment has a large effect on home care. Any economic analysis of prevention, treatment, and rehabilitation should account for the fraction of the annual monetary cost and loss of quality-adjusted life years that can be averted.

Entities:  

Mesh:

Year:  2007        PMID: 17420375     DOI: 10.1001/archopht.125.4.544

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  71 in total

1.  Associations among visual acuity and vision- and health-related quality of life among patients in the multicenter uveitis steroid treatment trial.

Authors:  Kevin D Frick; Lea T Drye; John H Kempen; James P Dunn; Gary N Holland; Paul Latkany; Narsing A Rao; H Nida Sen; Elizabeth A Sugar; Jennifer E Thorne; Robert C Wang; Janet T Holbrook
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-03-09       Impact factor: 4.799

2.  Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.

Authors:  Joshua D Stein; Paula Anne Newman-Casey; Tavag Mrinalini; Paul P Lee; David W Hutton
Journal:  Ophthalmology       Date:  2014-01-07       Impact factor: 12.079

Review 3.  Brain Machine Interfaces for Vision Restoration: The Current State of Cortical Visual Prosthetics.

Authors:  Soroush Niketeghad; Nader Pouratian
Journal:  Neurotherapeutics       Date:  2019-01       Impact factor: 7.620

4.  "Can we declare victory and move on?" The case against funding burden-of-disease studies.

Authors:  Steven Kymes
Journal:  Pharmacoeconomics       Date:  2014-12       Impact factor: 4.981

5.  A comparative effectiveness analysis of visual field outcomes after projected glaucoma screening using SD-OCT in African American communities.

Authors:  Dana M Blumberg; Reena Vaswani; Eva Nong; Lama Al-Aswad; George A Cioffi
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-01       Impact factor: 4.799

Review 6.  Corneal blindness and xenotransplantation.

Authors:  Vladimir Lamm; Hidetaka Hara; Alex Mammen; Deepinder Dhaliwal; David K C Cooper
Journal:  Xenotransplantation       Date:  2014-02-21       Impact factor: 3.907

7.  Natural history of age-related retinal lesions that precede AMD in mice fed high or low glycemic index diets.

Authors:  Karen A Weikel; Paul Fitzgerald; Fu Shang; M Andrea Caceres; Qingning Bian; James T Handa; Alan W Stitt; Allen Taylor
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-02       Impact factor: 4.799

8.  Current trends among pediatric ophthalmologists to decrease myopia progression-an international perspective.

Authors:  Ofira Zloto; Tamara Wygnanski-Jaffe; Sonal K Farzavandi; Rosario Gomez-de-Liaño; Derek T Sprunger; Eedy Mezer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-03       Impact factor: 3.117

9.  Visual Impairment and Blindness in Adults in the United States: Demographic and Geographic Variations From 2015 to 2050.

Authors:  Rohit Varma; Thasarat S Vajaranant; Bruce Burkemper; Shuang Wu; Mina Torres; Chunyi Hsu; Farzana Choudhury; Roberta McKean-Cowdin
Journal:  JAMA Ophthalmol       Date:  2016-07-01       Impact factor: 7.389

10.  Factors that influence the suitability of human organ-cultured corneas.

Authors:  T Röck; J Hofmann; S Thaler; M Bramkamp; K U Bartz-Schmidt; E Yoeruek; D Röck
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-08-20       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.